Design, Synthesis and Brain Uptake of LAT1-Targeted Amino Acid Prodrugs of Dopamine
- 1.6k Downloads
Drug delivery to the brain is impeded by the blood-brain barrier (BBB). Here, we attempted to enhance the brain uptake of cationic dopamine by utilizing the large amino acid transporter 1 (LAT1) at the BBB by prodrug approach.
Three amino acid prodrugs of dopamine were synthesized and their prodrug properties were examined in vitro. Their LAT1-binding and BBB-permeation were studied using the in situ rat brain perfusion technique. The brain uptake after intravenous administration and the dopamine-releasing ability in the rat striatum after intraperitoneal administration were also determined for the most promising prodrug.
All prodrugs underwent adequate cleavage in rat tissue homogenates. The prodrug with phenylalanine derivative as the promoiety had both higher affinity for LAT1 and better brain uptake properties than those with an alkyl amino acid -mimicking promoiety. The phenylalanine prodrug was taken up into the brain after intravenous injection but after intraperitoneal injection the prodrug did not elevate striatal dopamine concentrations above those achieved by corresponding L-dopa treatment.
These results indicate that attachment of phenylalanine to a cationic drug via an amide bond from the meta-position of its aromatic ring could be highly applicable in prodrug design for LAT1-mediated CNS-delivery of not only anionic but also cationic polar drugs.
KEY WORDSblood-brain barrier brain drug delivery dopamine large amino acid transporter 1 prodrugs
aromatic L-amino acid decarboxylase
area under the curve
central nervous system
glucose transporter 1
large neutral amino acid transporter 1
lower limit of quantification
brain permeability-surface area
ascorbic acid transporter
topological polar surface area
ACKNOWLEDGMENTS AND DISCLOSURES
Lauri Peura, Kalle Malmioja, Jarkko Rautio and Krista Laine share equal contribution to this work.
The authors would like to express their profound gratitude to laboratory technicians Helly Rissanen and Jaana Leskinen for their skillful assistance. Marko Lehtonen, M.Sc., is also acknowledged for his skillful help in the HPLC-EC-analytics, Tiina Kääriäinen, Ph.D., for her skillful help in the animal studies and Ewen MacDonald, Ph.D., for refining the English of this paper. We also thank Henna Härkönen, M.Sc., for the polar surface area calculations. The work was financially supported by the Graduate School of Pharmaceutical Research, the Academy of Finland (# 132637), the Orion-Farmos foundation, the Finnish Pharmaceutical Society, the Finnish Parkinson Foundation and the Emil Aaltonen Foundation.
- 12.Balakrishnan A, Jain-Vakkalagadda B, Yang C, Pal D, Mitra AK. Carrier mediated uptake of L-tyrosine and its competitive inhibition by model tyrosine linked compounds in a rabbit corneal cell line (SIRC)—strategy for the design of transporter/receptor targeted prodrugs. Int J Pharm. 2002;247(1–2):115–25.PubMedCrossRefGoogle Scholar
- 30.Smith QR, Allen DD. Methods in molecular medicine: the blood-brain barrier: biology and research protocols. In: Sukriti Nag, editors. Totowa, NJ: Humana Press Inc.; 2003. p. 209–218.Google Scholar
- 31.Krupka RM. Expression of substrate specificity in facilitated transport systems. JMB. 1990;117:69–78.Google Scholar
- 32.Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, et al. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther. 2005;313(3):1254–62.PubMedCrossRefGoogle Scholar